(CercleFinance.com) – Armistice Capital, acting on behalf of the Armistice Capital Master Fund, which it manages, told the AMF that it crossed the thresholds of 5% of the capital and voting rights of the company Erytech Pharma and hold, on behalf of the said fund, 9.92% of the capital and 9.47% of the voting rights of this company.
This crossing of thresholds results from the subscription to a capital increase of the company Erytech Pharma.